Curative Biotechnology announced that it has successfully completed its investigational new drug (IND) enabling tolerance and toxicology study of Metformin HCL solution by topical Instillation (eye drops) in rabbits.

“We are pleased to announce the successful completion of these important studies, outlined in our Pre IND meeting with the FDA," Paul Michaels, Chairman and President of Curative Biotechnology, said in a news release. "We are now able to move on to preparing the company’s first IND application to move our Metformin reformulation into a clinical trial to treat Intermediate dry age-related macular degeneration (AMD) and geographical atrophy (GA) resulting from AMD.”

“Both dry AMD and GA are currently unmet medical needs with no FDA approved efficacious treatment options. As previously announced, we will be conducting the first in human study under a CRADA (Cooperative Research and Development Agreement) with the National Eye Institute of the National Institutes of Health, in Bethesda Maryland," Mr. Michaels said.